Vancouver General Hospital

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Retrieved on: 
星期三, 五月 29, 2024
ACT, Patient, Prognosis, Survival, Amyloidosis, American Heart Association, Month, Risk, Food, ACC, NDA, European Medicines Agency, Calendar, University, ISA, Safety, Serum, ESC, PDUFA, AHA, Congress, Death, Cancer, Biomarker, Cox, Columbia University, Mortality, CVH, MAA, Vancouver General Hospital, American College, Webcast, CVM, Quality of life, TTR, Pharmaceutical industry

ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally administered, highly potent, small molecule stabilizer of TTR.

Key Points: 
  • ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally administered, highly potent, small molecule stabilizer of TTR.
  • BridgeBio will host an investor call on Wednesday, May 29th at 5:30 pm ET to discuss these results.
  • “The data presented at ISA confirm that improved stabilization as reflected in higher serum TTR levels is directly correlated with improved clinical outcomes.
  • Prior analyses from ATTRibute-CM demonstrated that the near-complete stabilization by acoramidis rapidly and durably increased serum TTR levels.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
星期二, 三月 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
星期二, 三月 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System

Retrieved on: 
星期四, 三月 7, 2024
SAN, Medical college, Medical College of Wisconsin, Vancouver General Hospital, DSM-IV codes, American College, ACMG, OGM, LGG, Medical genetics, DRS, Research, Cancer, Medical device

Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis

Key Points: 
  • Dr. Tara Spence from Vancouver General Hospital will present insights into her laboratory’s adoption of Stratys and its potential impact on hematological malignancy analysis
    A scientific platform presentation will feature Drs.
  • ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research.
  • The ACMG conference will be held March 12-16, 2024, in Toronto, Canada.
  • All scientific posters will be presented in Exhibit Halls DE.

Ondine Successfully Raised C$4.91 Million to Support Acceleration of Its Commercial Rollout of Nasal Decolonization to Prevent Healthcare-associated Infections

Retrieved on: 
星期三, 十二月 13, 2023
Medical Devices, Health, Hospitals, Surgery, Health Technology, Biotechnology, SSI, Nose, Patient, Fungus, FDA, Mupirocin, Vancouver General Hospital, Christianity in Singapore, Bacteria, Virus, Hospital, Society, HCA, Fungal infection, Bloodstream infections, Pharmaceutical industry

Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. will continue accelerating commercialisation of its proven nasal photodisinfection technology.

Key Points: 
  • Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. will continue accelerating commercialisation of its proven nasal photodisinfection technology.
  • This cutting-edge technology replaces topical antibiotics for the prevention of healthcare-associated infections (HAIs) and kills all types of pathogens – bacteria, viruses and fungi – without causing antimicrobial resistance.
  • The growing global focus on preventing HAIs post-surgery, coupled with the escalating challenge of antimicrobial resistance, has spurred heightened interest in Ondine’s photodisinfection technology.
  • The antibiotic mupirocin has been used for nasal decolonization for the prevention of HAIs since the 1980s.

Ondine Biomedical’s photodisinfection recommended as standard of care

Retrieved on: 
星期四, 十一月 16, 2023
Health, Medical Devices, Infectious Diseases, Surgery, Other Health, Pharmaceutical, Biotechnology, Spine, Vancouver General Hospital, Canadian Journal of Surgery, Patient, Nursing, Marketing

The study spanned an eight-year period and involved 13,493 patients with 8823 patients receiving Steriwave®.

Key Points: 
  • The study spanned an eight-year period and involved 13,493 patients with 8823 patients receiving Steriwave®.
  • The paper concludes that nasal photodisinfection should be the standard of care for all patients undergoing emergent or elective spine surgeries.
  • The eight-year study showed a 66.5% reduction (7.98% vs 2.67%, p
  • This study conclusively demonstrates that Steriwave is setting a new standard for safety and performance in infection control.”

Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia

Retrieved on: 
星期一, 十一月 6, 2023
Abdominal pain, Headache, Food, Vancouver, Thrombocytopenia, Physician, Health Canada, MD, FRCPC, Hemostasis, Edema, Bleeding, Nausea, Platelet transfusion, Vancouver General Hospital, Chronic liver disease, Risk, Swedish Orphan Biovitrum, ITP, Blood, University, CLD, Woman, Safety, Patient, Hospital, Platelet, Fatigue, Medical imaging, Birth control, Pharmaceutical industry, Avatrombopag, Fever

”The current treatment landscape for immune thrombocytopenia in Canada has left certain patients with limited options.

Key Points: 
  • ”The current treatment landscape for immune thrombocytopenia in Canada has left certain patients with limited options.
  • With today’s approval of Doptelet, patients now have an effective oral treatment option with no food-type restrictions or need for liver function monitoring,” said Dr. Charles H. Li, MD, FRCPC, Consultant Hematologist at Vancouver General Hospital and Clinical Associate Professor at the University of British Columbia.
  • For Sobi Media contacts, click here.
  • Pooled safety data for 128 patients with ITP support the safety and tolerability of DOPTELET.

DurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Retrieved on: 
星期一, 八月 14, 2023
Surgery, Medical Devices, Health, Clinical Trials, Cardiology, AVR, Pressure, Partnership, Failure, THV, Singapore Space and Technology Ltd, Calcification, Clinical trial, Viv, ASX, Multimedia, Vancouver General Hospital, SAP, USD, Aortic stenosis, Patient, Physician, Risk, OTC, TAVR, EFS, Hospital, Health Canada, Valve, Female, Medical device, Medical imaging, Pharmaceutical industry

DurAVR™ THV was implanted in a 79-year-old female who was previously implanted with a Trifecta surgical valve that had severely degenerated, causing debilitating symptoms.

Key Points: 
  • DurAVR™ THV was implanted in a 79-year-old female who was previously implanted with a Trifecta surgical valve that had severely degenerated, causing debilitating symptoms.
  • The intraoperative results after DurAVR™ THV was implanted were phenomenal, with a mean pressure gradient of 7mmHg, restoring near-normal physiology.
  • Today’s case demonstrated what we saw in preclinical testing, that DurAVR™ THV has the potential to offer superior gradients for ViV patients.
  • These outstanding results are not only best in class but deliver options for patients that were previously not seen with existing products.

First NHS pilot of Ondine Biomedical’s nasal photodisinfection for the prevention of post-surgical infections starts at Mid Yorkshire Teaching NHS Trust

Retrieved on: 
星期二, 八月 1, 2023
Health, Infectious Diseases, Hospitals, Surgery, Pharmaceutical, Biotechnology, Infection, Hip, Consultant, The Ottawa Hospital, MRSA, Vancouver General Hospital, Trust, Innovation, Pain, Hospital, Patient, The Mid Yorkshire Hospitals NHS Trust, NHS trust, NICE, Pharmaceutical industry

Mid Yorkshire Teaching NHS Trust has this week started the first UK pilot evaluation of nasal photodisinfection for the prevention of surgical site infections.

Key Points: 
  • Mid Yorkshire Teaching NHS Trust has this week started the first UK pilot evaluation of nasal photodisinfection for the prevention of surgical site infections.
  • The six-month pilot will see 500 elective hip and knee surgery patients nasally decolonized using Ondine Biomedical’s Steriwave® nasal photodisinfection prior to their surgery.
  • Steriwave is already in use at a number of hospitals across Canada, including Vancouver General Hospital and The Ottawa Hospital, and has demonstrated significant improvement in post-surgical outcomes including lower rates of infection, reduced patient length of stay, fewer readmissions, and lower rates of antibiotic prescribing.i,ii,iii
    Dr Stuart Bond, Consultant antimicrobial pharmacist & Director of Innovation at Mid Yorkshire Teaching NHS Trust commented: “We are very pleased to be the first NHS Trust in the UK to pilot this exciting, non-antibiotic method of preventing infections after surgery.
  • Although infections after hip and knee surgeries are rare, we know that they lengthen patients’ stay in hospital, complicate the recovery process, and cause significant pain and suffering.

CHAIR 2022 Leadership Award Winners – Healthcare

Retrieved on: 
星期四, 六月 8, 2023
Yee, Infection prevention and control, Molecular biology, Infection, BC Centre of Excellence, Occupational safety and health, Medical Affairs Bureau, Canadian Centre for Occupational Health and Safety, Safety, Vancouver General Hospital, Provincial, Provincial Health Services Authority, Lions Gate Hospital, Reinecke, Organization, Safe, Vancouver Coastal Health, Medical director, IPAC, Health, Colombians, Microbiology, Nursing

"CHAIR wants to recognize John's passion and leadership in embracing new ideas around copper alloy engineered infection reduction materials to enhance the safety of the staff, residents, and families of Yee Hong Centre for Geriatric Care."

Key Points: 
  • "CHAIR wants to recognize John's passion and leadership in embracing new ideas around copper alloy engineered infection reduction materials to enhance the safety of the staff, residents, and families of Yee Hong Centre for Geriatric Care."
  • "Infection control in general, and in healthcare in particular, needs to be innovative and passive to reduce our reliance on harsh chemicals and manual disinfection systems.
  • CHAIR is an excellent forum to bring these innovations and systems to the attention of regulators and organizations."
  • Said Dr. Wong, "The engineered space represents a crucial component to patient and healthcare worker safety.